NRX Pharmaceuticals Inc(NRXP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:59 PM ET (Korea 10/31 08:59)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.74 | Insider Own | 11.62% | Shs Outstand | 43.2M | Perf Week | -8.84% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 52.87% | Insider Trans | - | Shs Float | 38.3M | Perf Month | -20.35% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.21 | Inst Own | 27.6% | Short Float | 26.01% | Perf Quarter | -29.94% |
| Income | -0.02B | P/S | 28.99 | EPS this Y | 35.07% | Inst Trans | 13.87% | Short Ratio | 11.22 | Perf Half Y | -26.54% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -120.42% | Short Interest | 9.95M | Perf YTD | -16.24% |
| Book/sh | 0 | P/C | 3.68 | EPS past 3/5Y | 39.52% 38.42% | ROE | - | 52W High | -55.09% ($5.05) | Perf Year | -24.83% |
| Cash/sh | 0.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | -8209.79% | 52W Low | 40.12% ($1.62) | Perf 3Y | -31.21% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 67.07% | Gross Margin | 32.68% | Volatility(W/M) | 11.37% 7.46% | Perf 5Y | -97.76% |
| Dividend TTM | - | EV/Sales | 21.49 | Sales Y/Y TTM | - | Oper. Margin | -588.13% | ATR (14) | 0.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.86 | EPS Q/Q | 55.24% | Profit Margin | -691.81% | RSI (14) | 29.9 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.86 | Sales Q/Q | - | SMA20 | -15.19% ($2.68) | Beta | 2.08 | Target Price | $38.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/17 | SMA50 | -25.81% ($3.06) | Rel Volume | 17.64 | Prev Close | $2.66 |
| Employees | 29 | LT Debt/Eq | - | EPS/Sales Surpr. | -312.37% -17.2% | SMA200 | -23.52% ($2.97) | Avg Volume(3M) | 0.89M | Price | $2.27 |
| IPO | 2017/12/4 | Option/Short | Yes/Yes | Trades | 37797 | Volume | 15,641,031 | Change | -14.66% |
💊 A clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders and life-threatening severe diseases. It focuses on areas with significant unmet medical needs, such as major depressive disorder with suicidal ideation, and its core business is the clinical development of candidate compounds and the regulatory approval process.
Over the past 1 year, on the lower side
55% below its 1-year high.
Traded more than usual. That is 1764% of its average volume.
NRXP has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +35.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,899. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #359 of 597 in the industry
Based on market cap of $98M.
PMVP#356 PMV Pharmaceuticals Inc $99M PER - 
CBUS#357 Cibus Inc $99M PER - 
VANI#358 Vivani Medical Inc $98M PER - NRXP#359 NRX Pharmaceuticals Inc $98M PER - 
KZIA#360 Kazia Therapeutics Limited ADR $97M PER - 
FAQ
What kind of company is NRXP?
NRXP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NRXP?
The market cap of NRXP is approximately $98M, ranking 4,472 within its sector.
What is the 52-week high and low for NRXP?
NRXP has recorded a 52-week high of $5.05 and a low of $1.62.
